Bringing the fundamentals into focus…
Back to Arbutus Biopharma Corporation
How Arbutus Biopharma Corporation stacks up
ABUS · against 476 other Healthcare companies of similar size
Valuation
96/ 100
Near the top of its peers.
Ranked #16 of 477 · scores higher than 96% of peers
Bars: peers in each 10-point band of the valuation score57 peers with a valuation score of 90–100, including ABUS · Click a bar to see the companies
Why valuation scores 96?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -3.2% vs peer median 0.0%
- more operating profit (EBITDA) for the company's total value: stronger than 95% of peers. EBITDA yield: 21.6% vs peer median 4.0%
- higher earnings for the price paid: stronger than 99% of peers. Earnings yield: 19.9% vs peer median 1.5%
Metric by metric
Position: dot = ABUS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ABUS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 465 reported | 20.4% | 0.6% | 98% | 30% | |
| EBITDA yieldHigher is better · 482 reported | 20.7% | 3.6% | 95% | 50% | |
| Free cash flow yieldHigher is better · 200 reported | -4.1% | -4.9% | 52% | 20% | |
| Book yieldHigher is better · 477 reported | 33.7% | 45.6% | 33% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ABUS| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 13 | 326M EUR (≈$359M) | 97 | 75 | |
| 16 | 3.8B HKD (≈$486M) | 96 | 56 | |
| 16 | 72.6B JPY (≈$494M) | 96 | 58 | |
| 16 | 44.2B JPY (≈$301M) | 96 | 64 | |
| 16 | 595M USD | 96 | 97 | |
| 16 | 433M USD | 96 | 81 | |
| 16 | 810M USD | 96 | 69 | |
| 16 | 578M USD | 96 | 73 | |
| 23 | 6.6B HKD (≈$840M) | 95 | 71 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score